TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
RemeGen Co. Ltd. Class H ( (HK:9995) ) has shared an update.
RemeGen Co., Ltd. has entered into a licensing agreement with Santen Pharmaceutical (China) Co., Ltd., granting Santen China exclusive rights to develop, manufacture, and commercialize the RC28-E Injection in Greater China and several Southeast Asian countries. This agreement, which includes significant upfront, milestone, and sales payments, is expected to accelerate market access for RC28-E, enhancing patient coverage and shortening its commercialization cycle. The collaboration is seen as beneficial for RemeGen’s shareholders and aligns with the company’s strategic interests.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a Chinese joint stock company specializing in the development of innovative biopharmaceuticals, with a focus on ocular neovascular diseases. The company has developed RC28-E, a VEGF/FGF dual-target fusion protein drug for treating retinal diseases.
Average Trading Volume: 11,978,745
Technical Sentiment Signal: Buy
Current Market Cap: HK$45.46B
See more data about 9995 stock on TipRanks’ Stock Analysis page.